Research and Markets: EpiCast Report: Dyslipidemia Epidemiology Forecast to 2022

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/glzpdg/epicast_report) has announced the addition of GlobalData's new report "EpiCast Report: Dyslipidemia Epidemiology Forecast to 2022" to their offering.

“EpiCast Report: Dyslipidemia Epidemiology Forecast to 2022”

Urbanization a Concern in India's Growing Dyslipidemia Problem

Lifestyle factors, including a sedentary lifestyle and high caloric and alcohol intake are contributing to an increase in prevalent cases of dyslipidemia across India, says research and consulting firm The authors.

The company's new epidemiology report* forecasts the number of dyslipidemia sufferers across the south Asian nation to climb from 192.7 million in 2012 to 245 million by the end of 2022 - a growth of 27% in just 10 years. The authors attributes this jump in prevalent cases primarily to the expected continuation of healthy population growth.

The nation with the second largest increase across the nine countries studied in the report, China, is predicted to increase by a comparatively modest 15% during the same period - from 84.7 million prevalent cases in 2012 to 97.1 million a decade on.

The authors's epidemiologists forecast that the prevalent cases of dyslipidemia in the nine major markets (the US, China, Japan, India and the five top European markets) will increase from 444 million cases in 2012 to 522 million cases in 2022 at an Annual Growth Rate (AGR) of 1.76%.

This report provides an overview of the risk factors and global trends of dyslipidemia in seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan) in addition to two emerging markets -- India and China.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by The authors's team of industry experts.

Key Topics Covered:

1.1 List of Tables

1.2 List of Figures

2 Introduction

3 Epidemiology

4 Appendix

For more information visit http://www.researchandmarkets.com/research/glzpdg/epicast_report.

Source: GlobalData